GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

The US Food and Drug Administration (FDA) has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

The FDA has accepted the BLA for lecanemab-irmb SC for weekly maintenance dosing in the treatment of early Alzheimer disease.

where attendees will also be able to see the highly-anticipated dataset with Eisai/Biogen's amyloid-targeting drug lecanemab. HMTM previously failed a phase 3 trial reported in 2016, and it ...